Efficacy and safety of rituximab therapy for systemic lupus erythematosus:a systematic review and meta-analysis

作     者：Lan LAN Fei HAN Jiang-hua CHEN 

作者机构：Department of Kidney Disease Center the First Affiliated Hospital School of Medicine Zhejiang University Hangzhou 310003 China 

出 版 物：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 (浙江大学学报（英文版）B辑（生物医学与生物技术）)

年 卷 期：2012年第13卷第9期

页      面：731-744页

核心收录：

学科分类：1002[医学-临床医学] 100206[医学-皮肤病与性病学] 10[医学] 

主　　题：Systemic lupus erythematosus Rituximab Meta-analysis 

摘      要：Objective:To review the efficacy and safety of rituximab therapy for systemic lupus erythematosus(SLE).Methods:We searched for randomized controlled trails and observational studies that evaluated the effect of rituximab based on the systemic lupus erythematosus disease activity index(SLEDAI),British Isles lupus assessment group index(BILAG),urine protein levels,and the prednisolone dose,and had adequate data to calculate the mean,standard deviation(SD),and 95% confidence intervals,and to systematically review and meta-analyze observational studies with fixed effects model or random effects ***:We included 2 randomized controlled studies and 19 observational clinical *** summarized the data from the 19 observational studies,analyzed the heterogeneity of the literature,and then used fixed effect model or random effect model for statistical *** SLEDAI,BILAG,and urine protein levels and the prednisolone dosage were decreased after rituximab treatment,and the decreases in the BILAG,urine protein levels,and the prednisolone dose were found to be significant(P0.05),when compared with baseline *** s adverse effects generally could be controlled with an effective dosing ***:Although there are still controversies about rituximab s treatment on SLE,but our study had showed that rituximab had favorable effects on refractory *** long-term efficacy and safety of rituximab require further study.